Merck & Co.
AWARDS
NEWS
With the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting ongoing, there are hundreds of newsworthy stories. Here is a few of our top picks so far.
Despite the advances in personalized medicine, a new survey of 1,001 Americans shows that the majority are not familiar with the concept.
Merck & Co’s anti-PD-1 therapy Keytruda dazzled in its pivotal Phase III KEYNOTE-407 trial.
Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.
Moderna Therapeutics and Merck expanded their 2016 collaboration deal to develop and commercialize personalized messenger RNA (mRNA) cancer vaccines. The new deal will include mRNA cancer vaccines that share antigens, including mRNA-5671, Moderna’s mRNA KRAS cancer vaccine.
According to Biosimilarpipeline, more than 660 companies worldwide have about 700 biosimilars in development.
JOBS
IN THE PRESS